JOE “SKIP” G.N. GARCIA, MD

Founder And Chief Executive Officer

skip@aqualungtherapeutics.com

University of Arizona Endowed Merlin K. DuVal MD Professor of Medicine and an elected member of the National Academy of Medicine. Dr. Garcia is a internationally recognized physican-scientist with over 30 years of research experience in pulmonary disease. For more information, click here.

EDDIE T. CHIANG, MA

Chief Operating Officer

eddie@aqualungtherapeutics.com

With over 15 years of high-level academic health sciences research and administrative experience, Mr. Chiang is employee #2 of Aqualung overseeing all day-to-day aspects of the research and development operations of eNamptor™. His research training is in pulmonary vascular biology, and he has contributed to the NAMPT project as the research transitions from benchside to bedside.

STAN MIELE, BA

Chief Business Strategy Officer

stan@aqualungtherapeutics.com

A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc. He will assist with Aqualung Therapeutics global alliances and helping the company move toward accelerating the pipeline and moving eNamptor toward commercialization.

SARA M. CAMP, BA

Chief Research Officer

sara@aqualungtherapeutics.com

With over 15 years experience with the Garcia research group, Ms. Camp specializes in the genomic and proteomic studies of inflammatory lung injury. She is responsible for overseeing the scientific research development of eNamptor™, a fully human anti-NAMPT monoclonal antibody for treating ventilator-induced lung injury (VILI).

Mariam Morris

Chief Financial Officer (Advisor)

Ms. Morris, age 51, serves as Aqualung’s CFO (advisor), since October 2018. Prior to Aqualung, she served as the Chief Financial Officer of Cerecor from May 2015 through August 2018. While at Cerecor, she completed the Company’s IPO and raised over $28 million in financings, in-licensed and out-licensed key assets, and completed two corporate acquisitions. She was responsible for the Company’s financial and corporation operations, investor relations, and served as the board’s secretary. Prior to joining Cerecor, Ms. Morris was the sole proprietor of Mariam Morris CPA, a full-service tax, accounting and business consulting firm, which she founded in January 2009 and operated until May 2015 where she served as an advisor to many private and public biotechnology companies. She served as the Chief Financial Officer of Sucampo Pharmaceuticals, Inc. from February 2004 to July 2009, where she completed the Company’s IPO and raised over $56 million in financings. From 1991 until 2001, Ms. Morris was and managing auditor for PricewaterhouseCoopers. Ms. Morris received her B.B.A. in Accounting from Texas Tech University and her M.S. in Taxation from Old Dominion University. Ms. Morris is a Certified Public Accountant in the State of Texas and a member of the TSCPA and AICPA.